Company news

Cocrystal Pharma, Inc. news in 2020

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses

December 21, 2020

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

November 15, 2020

Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

October 1, 2020

Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares

August 30, 2020

Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million

August 25, 2020

Cocrystal Pharma Announces $10.0 Million Bought Deal Offering

August 25, 2020

Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

August 5, 2020

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

August 3, 2020

Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

May 13, 2020

Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs

May 10, 2020

Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

April 21, 2020

Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors

April 19, 2020

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

March 29, 2020

Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

March 10, 2020

Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

March 8, 2020

Cocrystal Pharma Announces Plans to Advance Coronavirus Program

March 5, 2020

Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

February 27, 2020

Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market

February 26, 2020

Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds

February 23, 2020

Cocrystal Pharma, Inc. announces closing of $2.2 million registered direct offering

February 2, 2020

Cocrystal Pharma, Inc. prices $2.2 million registered direct offering

January 28, 2020

Decks in 2020